Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 4/2015

01-04-2015 | Neuroimaging (DJ Brooks, Section Editor)

The Role of Neuroinflammation in Dementias

Authors: Giuseppe Pasqualetti, David J. Brooks, Paul Edison

Published in: Current Neurology and Neuroscience Reports | Issue 4/2015

Login to get access

Abstract

The molecular mechanism of neuronal loss and synaptic damage in Alzheimer’s disease (AD), Parkinson’s disease dementia (PDD), frontotemporal dementia (FTD) and Lewy body dementia (LBD) is poorly understood and could differ among different types of neurodegenerative processes. However, the presence of neuroinflammation is a common feature of dementia. In this setting, reactive microgliosis, oxidative damage and mitochondrial dysfunction are associated with the pathogenesis of all types of neurodegenerative dementia. Moreover, an increased body of evidence suggests that microglia may play a central role in AD progression. In this paper, we review the scientific literature on neuroinflammation related to the most common neurodegenerative dementias (AD, PDD, FTD and LBD) focussing on the possible molecular mechanisms and the available clinical evidence. Furthermore, we discuss the neuroimaging techniques that are currently used for the study of neuroinflammation in human brain.
Literature
1.
Prince M et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63–75. e2.PubMedCrossRef
2.
Emre M, Cummings JL, Lane RM. Rivastigmine in dementia associated with Parkinson’s disease and Alzheimer’s disease: similarities and differences. J Alzheimers Dis. 2007;11(4):509–19.PubMed
3.
Petersen RC et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58(12):1985–92.PubMedCrossRef
4.
5.
Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson’s disease. Mov Disord. 2011;26(6):1049–55.PubMedCrossRef
6.
Iannaccone S et al. In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson’s disease. Parkinsonism Relat Disord. 2013;19(1):47–52.PubMedCrossRef
7.
Varnum MM, Ikezu T. The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer’s disease brain. Arch Immunol Ther Exp (Warsz). 2012;60(4):251–66.CrossRef
8.
McGeer PL et al. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology. 1988;38(8):1285–91.PubMedCrossRef
9.
Sastre M et al. Inflammatory risk factors and pathologies associated with Alzheimer’s disease. Curr Alzheimer Res. 2011;8(2):132–41.PubMedCrossRef
10.
McGeer PL, Itagaki S, McGeer EG. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol. 1988;76(6):550–7.PubMedCrossRef
11.
Imamura K et al. Cytokine production of activated microglia and decrease in neurotrophic factors of neurons in the hippocampus of Lewy body disease brains. Acta Neuropathol. 2005;109(2):141–50.PubMedCrossRef
12.
Mrak RE, Griffin WS. Common inflammatory mechanisms in Lewy body disease and Alzheimer disease. J Neuropathol Exp Neurol. 2007;66(8):683–6.PubMedCrossRef
13.
Morales I et al. Neuroinflammation in the pathogenesis of Alzheimer’s disease. A rational framework for the search of novel therapeutic approaches. Front Cell Neurosci. 2014;8:112.PubMedCentralPubMed
14.
Heneka MT, O’Banion MK. Inflammatory processes in Alzheimer’s disease. J Neuroimmunol. 2007;184(1–2):69–91.PubMedCrossRef
15.
Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007;10(11):1387–94.PubMedCrossRef
16.
Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996;19(8):312–8.PubMedCrossRef
17.
Liu X et al. Age-dependent neuroinflammatory responses and deficits in long-term potentiation in the hippocampus during systemic inflammation. Neuroscience. 2012;216:133–42.PubMedCrossRef
18.
19.•
Cunningham C. Microglia and neurodegeneration: the role of systemic inflammation. Glia. 2013;61(1):71–90. doi:10.​1002/​glia.​22350. This article is an evidence-based review that reported the most significant articles related to role of neuroinflammation and the progression of chronic neurodegenerative disease.PubMedCrossRef
20.
21.
Jimenez S et al. Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer’s disease: age-dependent switch in the microglial phenotype from alternative to classic. J Neurosci. 2008;28(45):11650–61.PubMedCrossRef
22.
Tanaka S et al. Involvement of interleukin-1 in lipopolysaccaride-induced microglial activation and learning and memory deficits. J Neurosci Res. 2011;89(4):506–14.PubMedCrossRef
23.
[Abstracts of the 9th Conference on Alzheimer Disease, Kecskemet, Hungary, September 21–23, 2005]. Ideggyogy Sz, 2005. 58(9–10): p. 344–57.
24.
Tanaka S et al. Activation of microglia induces symptoms of Parkinson’s disease in wild-type, but not in IL-1 knockout mice. J Neuroinflammation. 2013;10:143.PubMedCentralPubMedCrossRef
25.
Heneka MT et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493(7434):674–8.PubMedCrossRef
26.
Langenfurth A et al. Membrane-type 1 metalloproteinase is upregulated in microglia/brain macrophages in neurodegenerative and neuroinflammatory diseases. J Neurosci Res. 2014;92(3):275–86.PubMedCrossRef
27.
Cunningham C et al. Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol Psychiatry. 2009;65(4):304–12.PubMedCentralPubMedCrossRef
28.
Cunningham C et al. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J Neurosci. 2005;25(40):9275–84.PubMedCrossRef
29.
Lunnon K et al. Systemic inflammation modulates Fc receptor expression on microglia during chronic neurodegeneration. J Immunol. 2011;186(12):7215–24.PubMedCrossRef
30.
Liu B, Hong JS. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther. 2003;304(1):1–7.PubMedCrossRef
31.
Dickson DW et al. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer’s disease. Glia. 1993;7(1):75–83.PubMedCrossRef
32.
Barger SW, Harmon AD. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature. 1997;388(6645):878–81.PubMedCrossRef
33.
DeGiorgio LA et al. Amyloid precursor protein gene disruption attenuates degeneration of substantia nigra compacta neurons following axotomy. Brain Res. 2002;938(1–2):38–44.PubMedCrossRef
34.
McGeer PL, McGeer EG. The alpha-synuclein burden hypothesis of Parkinson disease and its relationship to Alzheimer disease. Exp Neurol. 2008;212(2):235–8.PubMedCrossRef
35.
Yoshiyama Y et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53(3):337–51.PubMedCrossRef
36.
Lue LF et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol. 1999;155(3):853–62.PubMedCentralPubMedCrossRef
37.
Ferrari CC et al. Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra. Neurobiol Dis. 2006;24(1):183–93.PubMedCrossRef
38.
Wright AL et al. Neuroinflammation and neuronal loss precede Abeta plaque deposition in the hAPP-J20 mouse model of Alzheimer’s disease. PLoS ONE. 2013;8(4):e59586.PubMedCentralPubMedCrossRef
39.
de Pablos RM et al. Chronic stress enhances microglia activation and exacerbates death of nigral dopaminergic neurons under conditions of inflammation. J Neuroinflammation. 2014;11:34.PubMedCentralPubMedCrossRef
40.
Griffin EW et al. Cyclooxygenase-1-dependent prostaglandins mediate susceptibility to systemic inflammation-induced acute cognitive dysfunction. J Neurosci. 2013;33(38):15248–58.PubMedCentralPubMedCrossRef
41.
Hensley K et al. p38 kinase is activated in the Alzheimer’s disease brain. J Neurochem. 1999;72(5):2053–8.PubMedCrossRef
42.
Kim SH, Smith CJ, Van Eldik LJ. Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1 beta production. Neurobiol Aging. 2004;25(4):431–9.PubMedCrossRef
43.
Kielian T, Drew PD. Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation. J Neurosci Res. 2003;71(3):315–25.PubMedCrossRef
44.
Bassil F, et al. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification? Prog Neurobiol. 2014;118:1–18.
45.
Vandal M, et al. Insulin reverses the high-fat diet-induced increase in brain Aβ and improves memory in an animal model of Alzheimer disease. Diabetes. 2014;63:4291–301
46.
Ghosh S et al. Sustained interleukin-1beta overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer’s mouse model. J Neurosci. 2013;33(11):5053–64.PubMedCentralPubMedCrossRef
47.
Detrait ER et al. Peripheral administration of an anti-TNF-alpha receptor fusion protein counteracts the amyloid induced elevation of hippocampal TNF-alpha levels and memory deficits in mice. Neurochem Int. 2014;72:10–3.PubMedCrossRef
48.
Sun Q et al. Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer’s disease. J Alzheimers Dis. 2014;41(3):877–86.PubMedCentralPubMed
49.
Woodling NS et al. Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling. J Neurosci. 2014;34(17):5882–94.PubMedCentralPubMedCrossRef
50.
Imamura K et al. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains. Acta Neuropathol. 2003;106(6):518–26.PubMedCrossRef
51.
Hirsch EC, Hunot S. Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol. 2009;8(4):382–97.PubMedCrossRef
52.
Brochard V et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest. 2009;119(1):182–92.PubMedCentralPubMed
53.
Harms AS et al. MHCII is required for alpha-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J Neurosci. 2013;33(23):9592–600.PubMedCentralPubMedCrossRef
54.
Lee HJ et al. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem. 2010;285(12):9262–72.PubMedCentralPubMedCrossRef
55.
Halliday GM, Stevens CH. Glia: initiators and progressors of pathology in Parkinson’s disease. Mov Disord. 2011;26(1):6–17.PubMedCrossRef
56.
Lee HJ, Kim C, Lee SJ. Alpha-synuclein stimulation of astrocytes: potential role for neuroinflammation and neuroprotection. Oxidative Med Cell Longev. 2010;3(4):283–7.CrossRef
57.
58.
Tang W et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science. 2011;332(6028):478–84.PubMedCentralPubMedCrossRef
59.
Baker M et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442(7105):916–9.PubMedCrossRef
60.
Martens LH et al. Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury. J Clin Invest. 2012;122(11):3955–9.PubMedCentralPubMedCrossRef
61.
62.
Bellucci A et al. Presence of reactive microglia and neuroinflammatory mediators in a case of frontotemporal dementia with P301S mutation. Neurodegener Dis. 2011;8(4):221–9.PubMedCentralPubMedCrossRef
63.
Schmidt R et al. Early inflammation and dementia: a 25-year follow-up of the Honolulu-asia aging study. Ann Neurol. 2002;52(2):168–74.PubMedCrossRef
64.
Engelhart MJ et al. Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. Arch Neurol. 2004;61(5):668–72.PubMedCrossRef
65.
Jiang T et al. Triggering receptor expressed on myeloid cells 2 knockdown exacerbates aging-related neuroinflammation and cognitive deficiency in senescence-accelerated mouse prone 8 mice. Neurobiol Aging. 2014;35(6):1243–51.PubMedCrossRef
66.
67.
Rayaprolu S et al. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson’s disease. Mol Neurodegener. 2013;8:19.PubMedCentralPubMedCrossRef
68.
Rohn TT. The triggering receptor expressed on myeloid cells 2: “TREM-ming” the inflammatory component associated with Alzheimer’s disease. Oxidative Med Cell Longev. 2013;2013:860959.CrossRef
69.
Harold D et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet. 2009;41(10):1088–93.PubMedCentralPubMedCrossRef
70.
Hollingworth P et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet. 2011;43(5):429–35.PubMedCentralPubMedCrossRef
71.
72.
73.
Wang YL et al. Toll-like receptor 9 promoter polymorphism is associated with decreased risk of Alzheimer’s disease in Han Chinese. J Neuroinflammation. 2013;10(1):101.PubMedCentralPubMedCrossRef
74.
Block ML, Hong JS. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol. 2005;76(2):77–98.PubMedCrossRef
75.
Wynne AM, Henry CJ, Godbout JP. Immune and behavioral consequences of microglial reactivity in the aged brain. Integr Comp Biol. 2009;49(3):254–66.PubMedCrossRef
76.
Tucsek Z, et al. Obesity in aging exacerbates blood–brain barrier disruption, neuroinflammation, and oxidative stress in the mouse hippocampus: effects on expression of genes involved in beta-amyloid generation and Alzheimer’s disease. J Gerontol A Biol Sci Med Sci. 2014;69:1212–26.
77.
78.••
Boyd TD et al. GM-CSF upregulated in rheumatoid arthritis reverses cognitive impairment and amyloidosis in Alzheimer mice. J Alzheimers Dis. 2010;21(2):507–18. doi:10.​3233/​JAD-2010-091471. These authors showed that subcutaneous GM-CSF administration significantly reduced brain amyloidosis and completely reversed the cognitive impairment, while increasing hippocampal synaptic area and microglial density in mice model.PubMed
79.
Misiak B, Leszek J, Kiejna A. Metabolic syndrome, mild cognitive impairment and Alzheimer’s disease—the emerging role of systemic low-grade inflammation and adiposity. Brain Res Bull. 2012;89(3–4):144–9.PubMedCrossRef
80.
Doruk H et al. The relationship between body mass index and incidental mild cognitive impairment, Alzheimer’s disease and vascular dementia in elderly. J Nutr Health Aging. 2010;14(10):834–8.PubMedCrossRef
81.
82.
83.
Noble JM et al. Periodontitis is associated with cognitive impairment among older adults: analysis of NHANES-III. J Neurol Neurosurg Psychiatry. 2009;80(11):1206–11.PubMedCentralPubMedCrossRef
84.
McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology. 1996;47(2):425–32.PubMedCrossRef
85.
Ferraccioli G et al. Rheumatoid arthritis and Alzheimer’s disease: genetic and epigenetic links in inflammatory regulation. Discov Med. 2012;14(79):379–88.PubMed
86.
Aisen PS et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289(21):2819–26.PubMedCrossRef
87.
Soininen H et al. Long-term efficacy and safety of celecoxib in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2007;23(1):8–21.PubMedCrossRef
88.••
Leoutsakos JM et al. Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer’s disease anti-inflammatory prevention trial. Int J Geriatr Psychiatr. 2012;27(4):364–74. doi:10.​1002/​gps.​2723. This recent revision of the AD Anti-inflammatory Prevention Trial supports a beneficial role of NSAID only in the early, asymptomatic, phases of Alzheimer disease suggesting that neuroinflammation could be a crucial events in the neurodegeneration process.
89.
90.
Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18 Suppl 1:S210–2.PubMedCrossRef
91.
Matsuda R et al. Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naive ulcerative colitis during active and quiescent disease. Inflamm Bowel Dis. 2009;15(3):328–34.PubMedCrossRef
92.
93.
Chen H et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson’s disease. Ann Neurol. 2005;58(6):963–7.PubMedCrossRef
94.
Wahner AD et al. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology. 2007;69(19):1836–42.PubMedCrossRef
95.
96.
Frautschy SA et al. Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol. 1998;152(1):307–17.PubMedCentralPubMed
97.
Cagnin A, Gerhard A, Banati RB. In vivo imaging of neuroinflammation. Eur Neuropsychopharmacol. 2002;12(6):581–6.PubMedCrossRef
98.
Cosenza-Nashat M et al. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol. 2009;35(3):306–28.PubMedCentralPubMedCrossRef
99.
Shah F et al. Synthesis of the enantiomers of [N-methyl-11C]PK 11195 and comparison of their behaviours as radioligands for PK binding sites in rats. Nucl Med Biol. 1994;21(4):573–81.PubMedCrossRef
100.
Chauveau F et al. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging. 2008;35(12):2304–19.PubMedCrossRef
101.
102.
Yasuno F et al. Increased binding of peripheral benzodiazepine receptor in mild cognitive impairment-dementia converters measured by positron emission tomography with [(1)(1)C]DAA1106. Psychiatry Res. 2012;203(1):67–74.PubMedCrossRef
103.
Edison P et al. Microglia, amyloid, and cognition in Alzheimer’s disease: an [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis. 2008;32(3):412–9.PubMedCrossRef
104.
Cagnin A et al. In vivo detection of microglial activation in frontotemporal dementia. Ann Neurol. 2004;56(6):894–7.PubMedCrossRef
105.
106.
Lant SB RA, Thompson JC, Rollinson S, Pickering-Brown S, Snowden JS, Davidson YS, Gerhard A, Mann DM. Patterns of microglial cell activation in frontotemporal lobar degeneration. Neuropathol Appl Neurobiol. 2014;40:686–96.
107.
Maeda J et al. Novel peripheral benzodiazepine receptor ligand [11C]DAA1106 for PET: an imaging tool for glial cells in the brain. Synapse. 2004;52(4):283–91.PubMedCrossRef
108.
Wang M, Gao M, Zheng QH. Fully automated synthesis of PET TSPO radioligands [11C]DAA1106 and [18 F]FEDAA1106. Appl Radiat Isot. 2012;70(6):965–73.PubMedCrossRef
109.
Yasuno F et al. Increased binding of peripheral benzodiazepine receptor in Alzheimer’s disease measured by positron emission tomography with [11C]DAA1106. Biol Psychiatry. 2008;64(10):835–41.PubMedCrossRef
110.•
Venneti S, Lopresti BJ, Wiley CA. Molecular imaging of microglia/macrophages in the brain. Glia. 2013;61(1):10–23. doi:10.​1002/​glia.​22357. This review provides an interesting and updated overview of positron emission tomography (PET) and magnetic resonance (MR) imaging of microglia/macrophages in the brain.PubMedCentralPubMedCrossRef
111.•
112.
Kreisl WC et al. A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J Cereb Blood Flow Metab. 2013;33(1):53–8.PubMedCentralPubMedCrossRef
113.
Kreisl WC et al. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease. Brain. 2013;136(Pt 7):2228–38.PubMedCentralPubMedCrossRef
114.
Metadata
Title
The Role of Neuroinflammation in Dementias
Authors
Giuseppe Pasqualetti
David J. Brooks
Paul Edison
Publication date
01-04-2015
Publisher
Springer US
Published in
Current Neurology and Neuroscience Reports / Issue 4/2015
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-015-0531-7

Other articles of this Issue 4/2015

Current Neurology and Neuroscience Reports 4/2015 Go to the issue

Headache (RB Halker, Section Editor)

Behavioral Treatments for Migraine Management: Useful at Each Step of Migraine Care

Stroke (HP Adams, Section Editor)

The Relationship Between Herpes Zoster and Stroke

Neuro-Oncology (LE Abrey, Section Editor)

Molecular Biology of Pediatric Brain Tumors and Impact on Novel Therapies

Stroke (HP Adams, Section Editor)

Dietary Interventions to Lower the Risk of Stroke

Headache (RB Halker, Section Editor)

Inpatient Management of Migraine

Neurology of Systemic Diseases (J Biller, Section Editor)

Neurological Counterparts of Hyponatremia: Pathological Mechanisms and Clinical Manifestations